文献速递流行病学与生物统计临床试验与 GCP

角质形成细胞癌:综述

Keratinocyte Carcinoma: A Review.
PubMed 文献 · JAMA · 2026-01-01

多数可通过办公室内手术有效治疗,防晒可降低cSCC风险,患者建议至少每年进行皮肤检查。

要点

  • 角质形成细胞癌主要位于头颈部,BCC占40%-64%,cSCC占35%-45%。
  • 低复发风险者常用手术切除或刮除电干燥,高复发风险者常用Mohs手术。
  • 随机临床试验显示每日使用防晒霜降低cSCC风险(率比0.62;95%CI 0.38-0.99)。

研究设计与样本

  • 本文为综述,总结了角质形成细胞癌(包括BCC和cSCC)的临床特征、风险因素、治疗和预防。

主要发现

  • 角质形成细胞癌主要位于头颈部:BCC占40%-64%,cSCC占35%-45%。
  • 手术治疗后复发率:手术切除后BCC约3%、cSCC约5%;刮除电干燥后BCC约6%、cSCC约2%;Mohs手术后BCC约4%、cSCC约3%。
  • 诊断为角质形成细胞癌的患者5年内发生额外角质形成细胞癌的风险约40%。
  • 随机临床试验中,每日使用防晒霜组cSCC发生率为953/10万人年,对照组为1587/10万人年(率比0.62;95%CI 0.38-0.99)。

关键数值与推荐

  • 低复发风险(非复发、边界清晰、体积小、位于躯干和四肢)的角质形成细胞癌通常由皮肤科医生进行办公室内手术切除或刮除电干燥。
  • 高复发风险的角质形成细胞癌通常采用办公室内Mohs手术。
  • 基于证据的预防措施包括使用防晒霜。
  • 患者建议至少每年进行皮肤检查。

临床怎么用

  • 低复发风险的角质形成细胞癌通常采用办公室内手术切除或刮除电干燥治疗。
  • 高复发风险的角质形成细胞癌通常采用办公室内Mohs手术治疗。
  • 推荐患者至少每年进行皮肤检查。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Keratinocyte carcinomas are skin cancers that arise from keratinocytes and are composed of basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Keratinocyte carcinomas are common in North America, Australia, New Zealand, and Europe. Approximately 5.4 million keratinocyte carcinomas are diagnosed in the US annually. OBSERVATIONS: Keratinocyte carcinomas are primarily located on the head and neck (40%-64% of BCCs; 35%-45% of cSCCs). BCC typically presents as a pink, smooth, raised lesion or a pink to red, flat lesion. cSCC typically presents as a red, scaly, flat lesion (in situ tumors) or a red, firm, raised lesion with scale or erosion (invasive tumors). UV light exposure is the primary cause, and lighter skin pigmentation and skin phototype (eg, skin that more easily burns) are the primary risk factors. Other risk factors include older age, male sex, indoor tanning, history of precancerous lesions (actinic keratoses), history of keratinocyte carcinomas, and immunosuppression (eg, organ transplant). In-office surgical excision or curettage and electrodessication (in which the tumor is scraped away using a curette and the wound base is cauterized) is typically performed by a dermatologist for keratinocyte carcinomas with lower risk of recurrence, including those that are nonrecurrent and have well-defined borders, small size, and location on the trunk and extremities. After surgical excision, approximately 3% of BCCs and 5% of cSCCs recur; after curettage and electrodessication, approximately 6% of BCCs and 2% of cSCCs recur. For keratinocyte carcinomas at higher risk of recurrence, in-office Mohs surgery (a technique in which a dermatologist with specialized training removes the tumor in stages and evaluates the entire surgical margin pathologically using a microscope after each stage to ensure complete tumor excision) is typically used. After Mohs surgery, approximately 4% of BCCs and 3% of cSCCs recur. Patients diagnosed with keratinocyte carcinoma are at high risk of additional keratinocyte carcinomas (approximately 40% within 5 years). Evidence-based prevention of keratinocyte carcinoma involves use of sunscreen. In a randomized clinical trial, use of daily sunscreen decreased cSCC risk (rate ratio, 0.62; 95% CI, 0.38-0.99; 1587 cSCCs per 100 000 person-years in controls vs 953 per 100 000 person-years in sunscreen group). CONCLUSIONS AND RELEVANCE: Keratinocyte carcinoma, composed of BCC and cSCC, is the most common cancer in the US, with an estimated 5.4 million diagnoses annually. Most keratinocyte carcinomas are effectively treated with in-office surgical procedures. Patients with keratinocyte carcinoma are recommended to undergo a skin examination at least annually due to their high risk of developing additional skin cancers.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wehner MR. Keratinocyte Carcinoma: A Review. JAMA. 2026. PMID: 41165676. doi:10.1001/jama.2025.18749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。